FOLH1 and posterior cortical atrophy: In our previous studies, three novel PSMA-targeted ligands, namely PSMA-Q, PSMA-4PY and PSMA-BP have been selected due to their high affinity to PSMA, specific accumulation in PSMA+ tumors and better pharmacokinetic characteristics than PSMA-617, which indicate their therapeutic potential for PCa tumors [27,28,29].